IL-2 restores immune sytem. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


IL-2 restores immune sytem. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Posit Aware. 1995 May/Jun;:8. Unique Identifier : AIDSLINE AIDS/95700401
Grodeck B


Abstract: Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) found that intermittent infusions of IL-2, an immune system protein, boosted T-cells in some patients with HIV for more than two years--far longer than any current antiretroviral. NIAID studied the effects of intravenous IL-2 in combination with AZT or ddI in 25 people with HIV or AIDS. Of the ten patients with T-cell counts greater than 200 who started the study, six had increases of more than fifty percent after one year. Alternately, of the fifteen patients who started the study with T-cell counts fewer than 200, only two patients showed a fifty percent increase in cell counts. Side effects were considerably more pronounced in the remaining thirteen participants in that group, and no significant increases in T-cell counts were observed. IL-2 is a naturally occurring substance produced by the body. However, NIAID used recombinant DNA technology produced by Chiron Corporation in Emeryville, California for its studies. Several IL-2 clinical trials are currently enrolling.
Keywords: Clinical Trials CD4 Lymphocyte Count Didanosine/ADMINISTRATION & DOSAGE/THERAPEUTIC USE Drug Therapy, Combination Human HIV Infections/DRUG THERAPY/IMMUNOLOGY/*THERAPY Interleukin-2/ADVERSE EFFECTS/*THERAPEUTIC USE Zidovudine/ADMINISTRATION & DOSAGE/THERAPEUTIC USE NEWSLETTER ARTICLEKWDclinicaltrialscd4lymphocytecountdidanosine/administration&dosage/therapeuticusedrugtherapy,combinationhumanhivinfections/drugtherapy/immunology/KWDtherapyinterleukin-2/adverseeffects/KWDtherapeuticusezidovudine/administration&dosage/therapeuticusenewsletterarticle
951230
M95C3194

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .